NAUT
Nautilus Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.06
−4.63%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$2.18
From 52W high−47.85%
Volume6.39M
Market cap$262.15M
P/E (TTM)—
P/S (TTM)1379.7x
Div yield—
Key dataOct 16, 2026
Open
$2.18
From 52W high
−47.85%
Volume
6.39M
Market cap
$262.15M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
P/E (TTM)
—
RSI (14)
68.1
MomentumView details →
1D Return
−4.63%
YTD Return
+9.49%
SummaryUpdated Jun 1, 2026
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) is a development-stage life sciences company founded in 2016 and headquartered in Seattle, Washington. The company went public in August 2020 and is focused on developing revolutionary proteomics technology to unlock the complexity of the human proteome - the complete set of proteins produced by an organism. Nautilus is creating a platform that promises to dramatically advance protein analysis capabilities, potentially transforming how researchers study diseases, develop drugs, and understand biological processes at the molecular level.
Similar companies
Latest newsMore news →
Nautilus Biotechnology, Inc. mutually terminated its prior at-the-market equity offering program with TD Securities (USA), LLC as sales agent.35d agoNautilus Biotechnology, Inc. entered into a sales agreement to sell up to $125,000,000 of common stock through an at-the-market offering program, with TD Securities (USA), LLC acting as sales agent.35d agoNautilus Biotechnology reported Q2 2026 financial results with total revenue of $0.2 million and a net loss of $14.5 million.81d ago